Research & KnowledgeEvent: September 8, 2026
INFEX Therapeutics presented new Phase IIa data for RESP-X at ERS Congress 2026.
Published
Signal category
Research & Knowledge
Quote
“Infex Therapeutics presents new Phase IIa data for RESP-X at ERS Congress 2026”
— INFEX Therapeutics team
Company
INFEX Therapeutics
Vital new drugs for pandemic infections
- Industry
- Biotechnology Research
- Location
- Alderley Edge, GB
- Company size
- 24 employees
We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Founded 2016